MXPA06009334A - Substituted pyrazoline compounds, their preparation and use as medicaments - Google Patents

Abstract

The present invention relates to substitute pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

Description

SUBSTITUTED PIRAZOLINE COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICINES FIELD OF THE INVENTION The present invention relates to substituted pyrazoline compounds, to methods for their preparation, to medicaments comprising these compounds as well as to their use for the preparation of a medicament for the treatment of humans and animals.

BACKGROUND OF THE INVENTION Cannabinoids are compounds derived from the plant Cannabis sativa which is commonly known as marijuana. The most active chemical compound of the naturally occurring cannabinoids is tetrahydrocannabinol (THC), particularly? 9-THC. These naturally occurring cannabinoids as well as their synthetic analogues promote their physiological effects by binding to specific receptors coupled to the G protein, the so-called cannabinoid receptors. At the present time, two different types of recipients have been identified and cloned that join both the natural cannabinoids as to synthetic cannabinoids. These receptors, which are called CBi and CB2 are involved in a variety of physiological or pathophysiological processes in humans and animals, for example processes related to the central nervous system, the immune system, the cardiovascular system, the endocrine system, the respiratory system , the gastrointestinal tract or reproduction, as described for example in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Mari uana / Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L. and Barthe A. Eds., CRC Press, 1992. Thus, compounds, which have a high binding affinity for these cannabinoid receptors. and which are suitable for modulating these receptors, are useful in the prevention and / or treatment of disorders related to cannabinoid receptors. In particular, the CBi receptor is involved in many different disorders related to food intake such as bulimia or obesity, including obesity associated with type II diabetes (non-insulin dependent diabetes) and, thus, in the prophylaxis and / or treatment of these disorders suitable compounds can be used to regulate this receptor.

SUMMARY OF THE INVENTION Thus, it was an object of the present invention to provide new compounds for use as active substances in medicaments. In particular, these active substances must be suitable for the modulation of cannabinoid receptors, more particularly of type 1 cannabinoid receptors (CBi). Said object was achieved by providing the substituted pyrazoline compounds of general formula I given below, their stereoisomers, their corresponding salts and their corresponding solvates.

DETAILED DESCRIPTION OF THE INVENTION It has been discovered that these compounds have a high affinity for cannabinoid receptors, particularly for the CBi receptor, and that they act as modulators, for example antagonists, inverse agonists, or agonists, in these receptors. Therefore, they are suitable for the prophylaxis and / or treatment of various disorders related to the central nervous system, the immune system, the system cardiovascular, the endocrine system, the respiratory system, the gastrointestinal tract or reproduction in humans and / or animals, preferably in humans including infants, children and adults. Thus, in one of its aspects, the present invention relates to substituted pyrazoline compounds of general formula I wherein R1 represents an optionally at least monosubstituted phenyl group, R2 represents an optionally at least monosubstituted phenyl group, R represents a cycloaliphatic group optionally containing at least one heteroatom as a member of the ring, optionally at least monosubstituted, saturated or unsaturated, which may be condensed with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted, or R3 represents a moiety -NR4R5-, R4 and R5, identical or different, represent a hydrogen atom, an aliphatic radical optionally at least monosubstituted, unbranched or branched, saturated or unsaturated, a cycloaliphatic group optionally containing at least a heteroatom as ring member, optionally at least monosubstituted, saturated or unsaturated, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused to a Mono or polycyclic ring system optionally at least monosubstituted and / or linked via a linear or branched alkylene group, a -S02-R6- moiety or a -NR7R8- moiety, R6 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted, a cycloaliphatic group which optionally contains at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic and / or linked through a linear or branched alkylene group, R7 and R8, identical or different, represent a hydrogen atom, a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted, a cycloaliphatic group which optionally contains at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be be condensed with a mono or polycyclic ring system optionally at least monosubstituted and / or linked through a linear or branched alkylene group, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. It is very preferable that for the pyrazoline compounds of general formula I described above, the following conditions (negations) apply: that R and R do not represent at the same time a hydrogen atom, and that if one of the residues R4 and R5 represents a hydrogen atom or an alkyl group, which is optionally at least monosubstituted with an alkoxy group, an alkoxyalkoxy group, a halogen atom or a phenyl group, the other of these residues R4 and R5 does not represent a pyrid-2-yl group , which is optionally monosubstituted in the 5-position, a pyrid-5-yl group, which is optionally monosubstituted in the 2-position, a pyrimid-5-yl group, which is optionally monosubstituted in the 2-position, a pyridaz-3 group ilo, which is optionally monosubstituted in the 6-position, a pyrazin-5-yl group, which is optionally monosubstituted in the 2-position, a thien-2-yl group, which is optionally monosubstituted in the 5-position, a thien-2 group -ilo, which is optionally at least monosubstituted in the 4-position, a benzyl group, which is optionally monosubstituted in the 4-position of the ring, a phenethyl group, which is optionally monosubstituted in the 4-position of the ring, an optionally mono, di or trisubstituted phenyl group, a disubstituted phenyl group, in which the two substituents together form a -0CH20-, -0CH2CH20- or -CH2CH20- chain, which is optionally substituted with one or more halogen atoms or one or two methyl groups, an NH-phenyl moiety, wherein the phenyl group may be monosubstituted at the 4-position, and if one of the residues R4 and R5 represents an alkynyl group, the another of these residues R4 and R5 does not represent a phenyl group, which is optionally substituted at the 4-position, and if one of the radicals R4 and R5 represents a hydrogen atom or a linear or branched, saturated or unsaturated aliphatic radical, substituted or unsubstituted, the other of these residues R4 and R5 does not represent a substituted or unsubstituted thiazole group or a substituted or unsubstituted [1, 3, 4] thiadiazole group. A mono or polycyclic ring system according to the present invention relates to a mono- or polycyclic hydrocarbon ring system which may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, that is, it may be saturated, unsaturated or aromatic. Optionally, each of the rings of the mono or polycyclic ring system may contain one or more, for example 1, 2 or 3, heteroatoms as ring members, which may be identical or different and which may preferably be selected from the group consisting of N, 0, S and P, more preferably is selected from the group consisting of in N, 0 and S. Preferably, the polycyclic ring system can comprise two rings that are fused. The rings of the mono or polycyclic ring system preferably have 5 or 6 members. The term "condensate" according to the present invention means that a ring or ring system is attached to another ring or ring system, the terms "ringed" or "attached" being also used by those skilled in the art to refer to this type of joint. . If one or more of the residues R3-R8 represents or comprises a cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, which is substituted with one or more, for example 1, 2, 3 or 4, substituents, unless otherwise defined, each of the substituents can be independently selected from the group consisting of hydroxyl, fluorine, chlorine, bromine, branched or unbranched C? _5 alkoxy, branched or unbranched C? _6 alkyl , perfluoroalkoxy C? _4 branched or unbranched, branched or unbranched C1-4 perfluoroalkyl, oxo, amino, carboxyl, amido, cyano, nitro, -S02NH2, -CO-C ?4 alkyl, -SO-C ?4 alkyl, -S02-C alkyl ? 4, -NH-S02-C 1-4 alkyl, wherein C branched or unbranched C 1-4 alkyl and a phenyl group may be, in each case, more preferably selected from the group consisting of hydroxyl, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, oxo, CF 3 and a phenyl group. If one or more of the residues R3-R8 represents or comprises a cycloaliphatic group, which contains one or more heteroatoms as ring members, unless otherwise defined, each of these heteroatoms may be selected, preferably, from the group consists of N, O and S. Preferably a cycloaliphatic group may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S as ring members. Suitable saturated or unsaturated cycloaliphatic groups, optionally containing at least one heteroatom as ring member, optionally at least monosubstituted, may preferably be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homo-piperazinyl and morpholinyl. If one or more of the residues R3-R8 comprises a mono or polycyclic ring system, which is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless otherwise defined, each one of the substituents can be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C6-6 alkoxy, branched or unbranched C6-6 alkyl, branched or unbranched perfluoroalkoxyC4-4, perfluoroalkyl C1 -4 branched or unbranched, amino, carboxyl, oxo, amido, cyano, nitro, -S02N02, -CO-C1-4alkyl, -SO-C4alkyl, -S02-C1-4alkyl, -NH-S02 -C 1-4 alkyl, wherein the C 1-4 alkyl may be, in each case, branched or unbranched, and a phenyl group, more preferably selected from the group consisting of hydroxyl, F, Cl, Br, methyl, ethyl, methoxy , ethoxy, CF3, oxo and a phenyl group.

If one or more of the residues R1-R8 represents or comprises an aryl group, including a phenyl group, which is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless another is defined each substituent can be independently selected from the group consisting of a halogen atom (for example F, Cl, Br, I), a straight or branched C 1-6 alkyl group, a straight or branched C 1-6 alkoxyl group, a formyl group, a hydroxyl group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C alkyl group ? ~ 6, a cyano group, a nitro group, a carboxyl group, a -CO-0-C-6 alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD- moiety, a -SH , a -SC-C6_6 alkyl group, a -SO-C-C6_6 alkyl group, a -S-2-C6_6 alkyl group, a C-C6_6-S-C-alkyl alkylene group; 6, a-C6-C6-SO-C6-C6 alkylene group, a C6_6-S02-C6_6 alkyl group, a -H2- moiety, a NHR'- moiety or a moiety? R'R "-, wherein R 'and R" represent, independently, a linear or branched C? -6 alkyl group, a C? _6 alkyl group substituted with one or more hydroxyl groups and a C-alkylene group? _6-NRERF, in which RA and RB, identical or different, represent hydrogen or a C? -6 alkyl group, or RA and RB together with the bridge nitrogen atom form a heterocyclic ring system or saturated, mono or bicyclic, of 3-10 members, which may be at least monosubstituted with one or more C? _6 alkyl groups, identical or different and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring, Rc, RD, identical or different, represent a hydrogen atom, a C? _6 alkyl group, a -CO-O-C? _6 alkyl group, a C3_8 cycloalkyl groupan alkylene group C6-6-cycloalkyl C3_8, an alkylene group C6_6-0-C6_6 alkyl or a C6_6 alkyl group substituted with one or more hydroxyl groups, or Rc, RD together with the nitrogen atom bridge form a saturated, mono or bicyclic ring system of 3-10 members which may be at least monosubstituted with one or more substituents independently selected from the group consisting of a C? _6 alkyl group, a -CO-C alkyl group? 6, a -CO-O-C C-C6-alkyl group, a -CO-NH-C alquilo-C6 alkyl group, a -CS- HH-C ?6 alkyl group, an oxo group, an C-alkyl group ? -6 substituted with one or more hydroxyl groups, an alkylene group C? _6-0-alkyl C? _6 and a group -C0-? H2 and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring, and in which RE, RF, identical or different, represent hydrogen or a C? _6 alkyl group, or RE and RF together with the bridge nitrogen atom form a ring system saturated, mono or bicyclic 3-10 membered, which may be at least monosubstituted with one or more C? _6 alkyl groups identical or different and / or which may contain at least one other heteroatom additional selected from the group consisting of nitrogen, oxygen and sulfur as ring member. Preferred aryl groups, which may be optionally at least monosubstituted, are phenyl and naphthyl. If one or more of the residues R3-R8 represents or comprises a heteroaryl group, which is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless otherwise defined, each of the substituents can be independently selected from the group consisting of a halogen atom (for example F, Cl, Br, I), a linear or branched C? _e alkyl group, a linear or branched C?-6 alkoxy group, a group formyl, a hydroxyl group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C6-alkyl group, a cyano group, a carboxyl group, a -CO-O-alkyl group C5, a -C0- moiety NRARB-, a residue -C0-? H-? RcRD-, a -S-alkyl group C? _6, a group -SO-C? _6 alkyl, a group -S02-C? _6 alkyl, an -alkylene C group ? 6-S-C? _6 alkyl, a C? _6-SO-C6_6 alkyl group, a C? _6-S02-C? _6 alkyl group, a C? _6 alkyl group substituted with one or more hydroxyl groups and an -alkylene group C? _6-? RERF, in which RA, RB, identical od if they represent hydrogen or a C? _6 alkyl group, or RA and RB together with the bridge nitrogen atom form a saturated ring system, mono- or bicyclic, 3-10 membered, which may be at least monosubstituted with one or more C6-6 alkyl groups, identical or different, and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring, Rc, RD, identical or different, represent a hydrogen atom, a C? _6 alkyl group, a -CO-O-C? _6 alkyl group, a C3_8 cycloalkyl group, a C? _6 alkylene group ~ C3_8 cycloalkyl, an alkylene group C6-6-O-C6_6 alkyl or a C6_6 alkyl group substituted with one or more hydroxyl groups, or Rc, RD together with the bridge nitrogen atom, form a ring system saturated, mono or bicyclic, of 3-10 members which may be at least monosubstituted with one or more substituents independently selected from the group consisting of a C? _6 alkyl group, a -CO-C? _6 alkyl group, a group - CO-O-C C_6 alkyl, a -CO-NH-C alquilo_6 alkyl group, a -CS-NH-C C_6 alkyl group, an oxo group, a group C? -6 alkyl substituted with one or more hydroxyl groups, a C? _6-0 alkylene-C? _6 alkyl group and a -CO-NH2 group and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen , oxygen and sulfur as a member of the ring, and where RE, RF, identical or different, represent hydrogen or a C? _6 alkyl group, or RE and RF together with the bridge nitrogen atom form a saturated, mono or bicyclic ring system of 3-10 members, which can to be at least monosubstituted with one or more C? -6 alkyl groups identical or different and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member. The heteroatoms which are present as ring members in the heteroaryl radical, unless otherwise defined, can be independently selected from the group consisting of nitrogen, oxygen and sulfur. Preferably a heteroaryl radical may comprise 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S as ring members. Suitable heteroaryl groups, which may be at least optionally monosubstituted, may preferably be selected from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, benzo [1,2,5] thiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl, triazolyl and pyrazolyl, more preferably they can be selected from the group consisting of in thienyl, benzo [1, 2, 5] -thiodiazolyl, benzo [b] thiophenyl, imidazo [2, 1-b] thiazolyl, triazolyl and pyrazolyl. If one or more of the residues R-R8 represents or comprises an aliphatic group, such as an alkyl group, linear or branched, saturated or unsaturated, which is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless otherwise defined, each substituent it may be independently selected from the group consisting of hydroxyl, fluorine, chlorine, bromine, branched or unbranched C 1 -4 alkoxy, branched or unbranched C 1 -4 perfluoroalkoxy, branched or unbranched C 1 -4 perfluoroalkyl, amino, carboxyl, amido, cyano, nitro, -S? 2NH2, -CO-C? _4 alkyl, -SO-C? -4 alkyl, -S02-C? -4 alkyl, -? H-S02-C? _4 alkyl, the C 4 alkyl in each case branched or unbranched, and a phenyl group, more preferably can be selected from the group consisting of hydroxyl, F, Cl, Br, methoxy, ethoxy, CF 3 and a phenyl group. Preferred linear or branched, saturated or unsaturated aliphatic groups, which may be substituted with one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl , sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethynyl, propenyl, propynyl, butenyl and butynyl. If any of the residues R4-R8 represents or comprises a linear or branched alkylene group, said alkylene group may be preferably selected from the group consisting of -methylene - (CH2) -, ethylene - (CH2-CH2) -, n-propylene - (CH2-CH2-CH2) - or isopropylene - (-C (CH3) 2) - • Substituted pyrazoline compounds of the general formula I given above are preferred, wherein R1 represents an optionally at least monosubstituted phenyl group, R2 represents an optionally at least monosubstituted phenyl group, R3 represents a cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system optionally at less monosubstituted, or R3 represents an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system optional at least monosubstituted, or R3 represents a -NR4R5- moiety, R4 and R5, identical or different, represent a hydrogen atom, a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted, a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and or linked through a linear or branched alkylene group, a -S0-R6- moiety, or a -NR7R8- moiety, R6 represents an aliphatic group, linear or branched, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic group which optionally contains at least one heteroatom as ring member, saturated or unsaturated, optionally at less monosubstituted, which may be fused with a mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system and / or linked through a linear alkylene group or branched, R7 and R8, identical or different, represent a hydrogen atom, a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted, a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system and / or linked through a linear or branched alkylene group, optionally in the form of one of the stereoisomers, preferably enantiomers and diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, in which the following conditions are preferably applied (negations): that R4 and R5 do not represent at the same time a hydrogen atom, and that if one of the residues R4 and R5 represents an atom of hydrogen, a linear or branched aliphatic group, saturated or unsaturated, substituted or unsubstituted, the other of these residues R4 and R5 does not represent a substituted or unsubstituted pyridyl group, a substituted or unsubstituted pyrimidyl group, a pyridazyl group substituted or not replaced, a substituted or unsubstituted pyrazinyl group, a substituted or unsubstituted thienyl group, a substituted or unsubstituted benzyl group, a substituted or unsubstituted phenethyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenyl group that is fused (attached) to at least one ring or optionally substituted ring system, an -NH-phenyl moiety-the phenyl group being at least monosubstituted, a substituted or unsubstituted thiazole group, or a substituted or unsubstituted [1, 3, 4] thiadiazole group, may also be preferred are the substituted pyrazoline compounds of the general formula I given above in which R 1 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C 1-6 alkyl group, a group linear or branched C6-6 alkoxy, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R \ SH, SR ', SOR', S02R ', NH2, NHR', NR'R ", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR' R", R 'and R "representing each substituent, independently, C-alkyl ? -6 linear or branched, preferably R1 represents a phenyl group, which is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R1 represents a phenyl group, which is substituted with a chlorine atom in the 4-position, and R2-R8 have the meanings given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. Also substituted pyrazoline compounds are preferred. general formula I proportion above, wherein R 2 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C 1-6 alkyl group, a linear or branched C 1-6 alkoxyl group, an atom of halogen, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -RA SH, SR ', SOR', S02R ', NH2, NHR',? R'R ", - (C = 0) -NH2, - (C = 0 ) -? HR 'and - (C = 0) -NR' R ", where R 'and R" are represented for each substituent, independently, linear or branched C? -6 alkyl, preferably R2 represents a phenyl group which is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R2 is a phenyl group, which is disubstituted with two chlorine atoms at positions 2 and 4, and R1 and R3- R8 have the meanings given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding α-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. substituted pyrazoline compounds of the general formula I given above, wherein R3 represents a C3_8 cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be condensed with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents a 5- or 6-membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents a moiety -NRR5-, preferably R3 represents a C3_8 cycloaliphatic group optionally containing one or more nitrogen atoms as ring members, saturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted, or R3 represents a -NR4R5- moiety, more preferably R3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, each of these groups may be substituted with one or more C? _6 alkyl groups, or R3 represents a moiety -? R4R5- and R1, R2 and R-R8 have the meanings given above, optionally in of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a? -oxide corresponding thereto, a corresponding salt thereof, or a corresponding solvate thereof. In addition, the substituted pyrazoline compounds of the general formula I given above are preferred., wherein R 4 and R 5, identical or different, represent a hydrogen atom, a C?-6, branched or unbranched, saturated or unsaturated, optionally at least monosubstituted C,-6 aliphatic radical, a C 3-8 cycloaliphatic group optionally containing minus one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group of 5 or 6 members, which may be condensed with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a methylene group (-CH2) or an ethylene group (-CH2-CH2) -, a -S02-R6- moiety, or a moiety -NR7R8-, preferably one of these residues R4 and R5 represents a hydrogen atom and the other of these residues R and R5 represents a C3_8 cycloaliphatic group optionally containing at least one hete roátomo as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an at least monosubstituted mono or polycyclic ring system or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono- or polycyclic ring system, a moiety -S02-R6- or a moiety -NR7R8- or R4 and R5, identical or different, each represents a C? -6 alkyl group, more preferably one of these residues R4 and R5 represents a hydrogen atom and the other of these residues R4 and R5 represents an optionally at least monosubstituted pyrrolidinyl group, an optionally at least monosubstituted piperidinyl group, an optionally at least monosubstituted piperazinyl group, an optionally at least monosubstituted triazolyl group, a -S02-R6- moiety, or a moiety -NR7R8-, or R4 and R5, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-bu group tyl or a tert-butyl group, and R1-R3 and R6-R8 have the same meanings given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of stereoisomers, preferably enantiomers and / or diastereomers, in any ratio of mixture, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. Also preferred are the substituted pyrazoline compounds of the general formula I given above, wherein R6 represents a linear or branched, saturated or unsaturated, optionally at least monosubstituted C ?_6 aliphatic group, a C3_8 cycloaliphatic group optionally containing at least a heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system or an optionally at least monosubstituted, 5- or 6-membered aryl or heteroaryl group, which may be fused to a mono- or polycyclic ring system and / or linked through a methylene (-CH-) or ethylene (-CH2-CH2) -, preferably R6 represents a C6-6 alkyl group, an optionally at least monosubstituted saturated cycloaliphatic group , which may be condensed with a mono or polycyclic ring system, or a phenyl group, which is optionally substituted with one or more group s alkyl C? _ 6 / and R1-R5, R7 and R8 have the meanings given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. In addition, the substituted pyrazoline compounds of the general formula I given above are preferred in which R7 and R8, identical or different, represent a hydrogen atom, a C6-6 branched or unbranched, saturated or unsaturated aliphatic radical, optionally at less monosubstituted, a C3_8 cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or an aryl or optionally at least monosubstituted, 5- or 6-membered heteroaryl, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a methylene group (-CH2-) or ethylene (-CH2-CH2) ) -, preferably represent a hydrogen atom or an alkyl radical C? _6, and R? R6 have the same meanings given above, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or an N- corresponding oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. Particularly preferred are the compounds of the general formula I given below, wherein R1 represents a phenyl ring, which is monosubstituted with a halogen atom, preferably a chlorine atom, in its 4-position, R 2 represents a phenyl ring, which is disubstituted with two halogen atoms, preferably chlorine atoms, in its 2 and 4 positions, R 3 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a group morpholinyl or a moiety -NRR5-, R4 represents a hydrogen atom or a linear or branched C? -6 alkyl group, R5 represents a linear or branched Ci-e alkyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group, a triazolyl group, each of the heterocyclic rings can be substituted with one or more identical or different C? _6 alkyl groups, or a -S02-R6 residue, and R6 represents a phenyl group which is optionally substituted with one or more L-6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or an N-oxide corresponding thereto, or a corresponding salt thereof or a corresponding solvate thereof. More preferred are substituted pyrazoline compounds selected from the group consisting of: N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole- 3-carboxamide, [l, 2,4] -triazol-4-yl-amide of 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro- lH-pyrazole-3-carboxylic acid, 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro (4-methyl-piperazin-1-yl) -amide. -lH-pyrazole-3-carboxylic acid, 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid diethylamide, [5] - (4-chloro-phenyl) -l- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazol-3-yl] -piperidine-1-yl-methanone, N- [5- ( 4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazole-3-carbonyl] -4-methylphenylsufonamide, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. In another aspect of the present invention there is also provided a method for preparing compounds of °% / H substituted pyrazoline of the general formula given above, according to which at least one benzaldehyde compound of general formula II II wherein R1 has the meaning given above, is reacted with a pyruvate compound of general formula (III) (III) wherein G represents an OR group with R being a linear or branched C-l-6 alkyl radical, preferably an ethyl radical, or G represents a group 0"K with K being a cation, preferably a monovalent cation, more preferably an alkali metal cation, much more preferably a sodium cation, to give a compound of general formula (IV) IV wherein R1 has the meaning given above, which is isolated and / or optionally purified, and which is reacted with an optionally substituted phenylhydrazine of general formula (V) (V) or a corresponding salt thereof, wherein R2 has the meaning given above, in an inert atmosphere, to give a compound of general formula (VI) (SAW) wherein R1 and R2 have the meanings given above, which is optionally isolated and / or optionally purified, and which is optionally converted, under an inert atmosphere, to a compound of general formula (VII) (Vile) wherein the substituents R1 and R2 have the meanings given above and A represents a leaving group, by reaction with an activating agent, optionally isolating and / or optionally purifying said compound, and reacting at least one compound of general formula (VI) with a compound of general formula R3H, wherein R3 represents a moiety -NRR5-, R4 and R5 having the meanings given above, to give a substituted pyrazoline compound of general formula I, wherein R3 represents a moiety -NRR5-, and / or is reacted at least one compound of general formula (VII) with a compound of general formula R3H, wherein R3 has the meaning given above, to give a compound of general formula (I) given above, which is optionally isolated and / or optionally purified . The method of the invention is also illustrated in scheme I given below: Scheme I where R3 is different from -NR4R5 The reaction of the benzaldehyde compound of general formula II with a pyruvate compound of the general formula III is preferably carried out in the presence of at least a base, more preferably in the presence of an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide or of an alkali metal methoxide such as sodium methoxide, as described, for example, in Synthetic Communications, 26 (11), 2229- 33, (1996). The respective description is incorporated herein by reference and forms part of the description. Preferably, sodium pyruvate can be used as the pyruvate compound. Preferably, said reaction is carried out in a protic reaction medium, such as a C1-4 alkyl alcohol or mixtures thereof. Mixtures of such alcohols can also be used with water, for example ethanol / water. The reaction temperature, as well as the duration of the reaction, can vary over a wide range. The preferred reaction temperatures range from -10 ° C to the boiling point of the reaction medium. Suitable reaction times may vary, for example, from several minutes to several hours. It is also preferred that the reaction of the benzaldehyde compound of the general formula II with a pyruvate compound of the general formula III be carried out under acid catalysis conditions, more preferably by refluxing the mixture in dichloromethane in the presence of copper (II) trifluoromethanesulfonate as described, for example, in Synlett, (1), 147-149, 2001. The respective description is incorporated herein by reference and forms part of the description. The reaction of the compound of general formula (IV) with an optionally substituted phenylhydrazine of general formula (V) is preferably carried out in a suitable reaction medium, such as C? -4-alcohols or ethers such as dioxane or tetrahydrofuran, or mixtures of minus two of these compounds mentioned above. Also preferably, said reaction can be carried out in the presence of an acid, which organic acid can be such as acetic and / or inorganic acid such as hydrochloric acid. In addition, the reaction can also be carried out in the presence of a base such as piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, or a mixture of at least two of these bases can also be used. The reaction temperature, as well as the duration of the reaction, can vary over a wide range. Suitable reaction temperatures vary from room temperature, ie approximately 25 = C, to the boiling point of the reaction medium. The times of Suitable reactions may vary, for example, from several minutes to several hours. The carboxylic group of the compound of general formula (VI) can be activated for subsequent reactions by introducing a suitable leaving group according to conventional methods well known to those skilled in the art. Preferably, the compounds of general formula (VI) are converted into an acid chloride, an acid anhydride, a mixed anhydride, a C 4 alkyl ester or an activated ester such as p-nitrophenyl ester. Other well known methods for activating the acids include activation with N, N-dicyclohexylcarbodiimide or benzotriazole-N-oxotris (dimethylamino) phosphonium hexafluorophosphate (BOP)). If said activated compound of general formula (VII) is an acid chloride, it is preferably prepared by reaction of the corresponding acid of general formula (VI) with thionyl chloride or oxalyl chloride, said chlorinating agent also being used as the solvent. Preferably, an additional solvent can also be used. Suitable solvents include hydrocarbons such as benzene, toluene or xylene, halogenated hydrocarbons such as dichloromethane, chloroform or carbon tetrachloride, ethers such as diethyl ether, dioxane, tetrahydrofuran or dimethoxyethane. HE they can also use mixtures of two or more solvents of one class or two or more solvents of different kinds. The preferred reaction temperature range varies from 0 ° C to the boiling point of the solvent and the reaction times vary from several minutes to several hours. If said activated compound of general formula (VII) is a mixed anhydride, said anhydride can be preferably prepared, for example, by reaction of the corresponding acid of general formula (VI) with ethyl chloroformate in the presence of a base such as triethylamine or pyridine. , in a suitable solvent. The reaction of a compound of general formula (VII) with a compound of general formula HR3 to produce compounds of general formula I, wherein R3 represents a -NR4R5 moiety, is preferably carried out in the presence of a base such as triethylamine in a reaction medium such as methylene chloride. The temperature is preferably in the range from 02C to the boiling point of the reaction medium. The reaction time can vary over a wide range, for example, from several hours to several days. The reaction of the compound of general formula (VII) with a compound of general formula HR3 to give compounds of general formula I in which R3 represents a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system or a optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, may be carried out according to conventional methods well known to those skilled in the art, for example, de Pascual , A., J. Prakt Chem., 1999, 341 (7), 695-700; Lin, S. et al., Heterocycles, 2001, 55 (2), 265-277; Rao, P. et al., J. Org. Chem., 2000, 65 (22), 7323-7344, Pearson D.E and Buehler, C.A., Synthesis, 1972, 533-542 and references cited therein. The respective descriptions are incorporated herein by reference and form part of the present disclosure. Preferably, said reaction is carried out in the presence of a Lewis acid, which is preferably selected from the group consisting of FeCl3, ZnCl2 and A1C13, in a suitable reaction medium such as toluene, benzene, tetrahydrofuran or the like. The temperature is preferably in the range of from 0 = C to the boiling point of the reaction medium, more preferably from 15 to 25 aC. The reaction time can vary over a wide range, for example, from several minutes to several hours. The aforementioned reactions involving the synthesis of the 4,5-dihydro-pyrazole ring or the reaction of a compound comprising said ring, are carried out in an inert atmosphere, preferably nitrogen or argon, to avoid oxidation of the system of ring. During the processes described above, it may be necessary and / or desirable to protect the sensitive or reactive groups. The introduction of conventional protecting groups as well as their removal can be carried out by methods well known to those skilled in the art. If the substituted pyrazoline compounds of general formula (I) themselves are obtained in the form of a mixture of stereoisomers, particularly enantiomers or distereomers, said mixtures can be separated by conventional procedures known to those skilled in the art, for example, chromatographic methods. or fractional crystallization with chiral reagents. It is also possible to obtain pure stereoisomers by stereoselective synthesis. In another aspect the present invention relates to the compound optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or a corresponding salt thereof , or a corresponding solvate thereof, preferably as an intermediate product in a process for preparing substituted pyrazoline compounds of general formula (I).

In another aspect of the present invention there is also provided a process for the preparation of salts of substituted pyrazoline compounds of general formula (I) and stereoisomers thereof, wherein at least one compound of general formula (I) is reacted having at least one basic group with at least one inorganic and / or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media include, for example, any of those provided above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and nitric acid, and are suitable organic acids, for example, citric acid, maleic acid, fumaric acid, tartaric acid or derivatives thereof, p-toluenesulfonic acid , methanesulfonic acid or camphorsulfonic acid. In yet another aspect of the present invention there is also provided a process for the preparation of salts of substituted pyrazoline compounds of general formula (I) or stereoisomers thereof, wherein at least one compound of general formula (I) is reacted ) having at least one acid group with one or more suitable bases, preferably in the presence of a suitable reaction medium. The proper bases are, for example, hydroxides, carbonates or alkoxides, including suitable cations, derived from, for example, alkali metals, alkaline earth metals or organic cations, for example [NHnR4_n] +, wherein n is 0, 1, 2, 3 or 4 and R represents a branched or unbranched C? _4 alkyl radical. Suitable reaction media are, for example, any of those provided above. Solvates, preferably hydrates, of the substituted pyrazoline compounds of the general formula (I), of the corresponding stereoisomers, of the corresponding N-oxides or of the corresponding salts thereof can also be obtained by conventional methods known to those skilled in the art. The technique. Substituted pyrazoline compounds of general formula I, comprising saturated, unsaturated or aromatic rings containing nitrogen atoms, may also be obtained in the form of their N-oxides by methods well known to those skilled in the art. Those skilled in the art understand that the term "substituted pyrazoline compounds" as used herein is to be understood as encompassing derivatives such as ethers, esters, and also complexes of these compounds. The term "derivatives" as used in this application is defined herein with the meaning of a chemical compound that has undergone a chemical derivation from an active compound (active) to change (improve for pharmaceutical use) any of its physicochemical properties, especially a so-called prodrug, for example its esters and ethers. Examples of known methods for producing a prodrug of a certain acting compound are known to those skilled in the art and can be found for example in Krogsgaard-Larsen et al., Textbook of Drug design and Discovery, Taylor & Francis (April 2002). The respective description is incorporated herein by reference and forms part of the description. The purification and isolation of the substituted pyrazoline compounds of the invention of general formula (I), a stereoisomer, salt, or N-oxide, or corresponding solvate or any intermediate thereof can be carried out, if required, by conventional methods known to those skilled in the art, for example methods chromatographic or recrystallization. The substituted pyrazoline compounds of general formula (i) given below, their stereoisomers, their corresponding N-oxides, their corresponding salts and their corresponding solvates are toxicologically acceptable and, therefore, are suitable as pharmaceutically active substances for preparing medicaments. It has been found that the substituted pyrazoline compounds of the general formula I given below, their stereoisomers, their N-oxides, the corresponding salts and the corresponding solvates have a high affinity for cannabinoid receptors, particularly the cannabinoid receptors of type 1 (CBi) ie they are ligands selective for the receptor (CBi) and act as modulators, for example antagonists, inverse agonists, or agonists, on these receptors. In particular, these pyrazoline compounds show little or no development of tolerance during the treatment, particularly with respect to food intake, for example if the treatment is interrupted for a certain period of time and then the compounds of pyrazoline used inventively will once again show the desired effect. After finishing the treatment with the pyrazoline compounds, it is observed that the positive influence on body weight is maintained.

In addition, these pyrazoline compounds show a relatively weak affinity towards HERG channels, so a low risk of QT interval prolongation is expected for these compounds. In sum, the inventively used pyrazoline compounds are distinguished by a broad spectrum of beneficial effects, while at the same time showing relatively small unwanted effects, ie effects that do not contribute positively or even interfere with the patient's well-being. Therefore, another aspect of the present invention relates to a medicament comprising at least one substituted pyrazoline compound of general formula I, in which R1 represents an at least monosubstituted phenyl group, R2 represents an optionally at least monosubstituted phenyl group, R3 represents a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused to an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents a -NRR5- moiety , R4 and R5, identical or different, represent a hydrogen atom, a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted, a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated , optionally at least monosubstituted, which can be condensed with an optionally at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted and / or linked through a linear or branched alkylene group, a -S02-R- moiety, or a -NR7R8- moiety, provided that R4 and R5 do not simultaneously represent hydrogen, R6 represents a group linear or branched aliphatic, saturated or unsaturated, optionally at least monosubstituted, a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system , or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked through a linear or branched alkylene group, R7 and R8, identical or different, represent a hydrogen, a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted, a cycloaliphatic group containing opc at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an at least monosubstituted mono or polycyclic ring system, or an optionally at least monosubstituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a linear or branched alkylene group, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients. A mono or polycyclic ring system according to the present invention relates to a mono- or polycyclic hydrocarbon ring system which may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, that is, it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono or polycyclic ring system may contain one or more, for example 1, 2 or 3, heteroatoms as ring members, which may be identical or different and which may preferably be selected from the group consists of N, 0, S and P, more preferably they are selected from the group consisting of N, 0 and S. Preferably, the polycyclic ring system may comprise two rings that are fused. The rings of the mono or polycyclic ring system preferably have 5 or 6 members. The term "condensate" according to the present invention means that a ring or ring system is attached to another ring or ring system, the terms "ringed" or "attached" being also used by those skilled in the art to designate this kind of joint. . If one or more of the residues R3-R8 represents or comprises a cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, which is substituted with one or more, for example 1, 2, 3 or 4, substituents, unless otherwise defined, each substituent may be independently selected from the group consisting of hydroxyl, fluoro, chloro, bromo, branched or unbranched C6-6 alkoxy, branched or unbranched C6-6 alkyl, branched or unbranched C 1 _ 4 perfluoroalkoxy, branched or unbranched C 1 _ 4 perfluoroalkyl, oxo, amino, carboxyl, amido, cyano, nitro, -S02NH 2, -CO-C 1 -4 alkyl, -SO-C 1 -4 alkyl / - S02-C C_4alkyl, -NH-S02-C alquilo_alkyl, wherein C C_4alkyl may be, in each case case, branched or unbranched, and a phenyl group, most preferably being selected from the group consisting of hydroxyl, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, oxo, CF3 and a phenyl group. If one or more of the residues R3-R8 represents or comprises a cycloaliphatic group, which contains one or more heteroatoms as ring members, unless otherwise defined, each of these heteroatoms may preferably be selected from the group consisting of N, 0 and S. Preferably a cycloaliphatic group may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of N, 0 and S as ring members. Saturated or unsaturated cycloaliphatic groups, optionally containing at least one heteroatom as ring member, optionally at least monosubstituted, may preferably be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl , cycloheptenyl, cyclooctenyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl and morpholinyl. If one or more of the residues R3-R8 comprises a mono- or polycyclic ring system which is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless otherwise, each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C6-6 alkoxy, branched or unbranched C6-6 alkyl, branched C1-4 perfluoroalkoxy or unbranched, branched or unbranched C 1 _ 4 perfluoroalkyl, amino, carboxyl, oxo, amido, cyano, nitro, -SO 2 NH 2, -CO-C 1-4 alkyl, -SO-C 1-4 alkyl, -S 0 2-C alkyl? _4, -NH-S02-C 1-4 alkyl, C 1-4 alkyl being, in each case, branched or unbranched, and a phenyl group, being more preferably selected from the group consisting of hydroxyl, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF3, oxo and a phenyl group. If one or more of the residues R1-R8 represents or comprises an aryl group, including a phenyl group, which is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless another is defined Each substituent can be independently selected from the group consisting of a halogen atom (F, Cl, Br, I), a linear or branched C ?_6 alkyl group, a linear or branched C ?_6 alkoxyl group, a formyl group, a hydroxyl group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C6_6 alkyl group, a cyano group, a nitro group, a group carboxyl, a -CO-O-C C6 alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD- moiety, a -SH, a group -S-alkyl C? _6, a group -SO-alkyl C? -6, a group -S02-alkyl C? _6, a -alkylene group C? _6-S-alkyl C? _6 , a-C6_6-SO-C6_6alkylene group, a C6_6-S02-C6_6alkyl-C6_alkyl group, a -NH2-, a NHR'-moiety or a NR'R-moiety, representing R 'and R "independently a straight or branched C6-6 alkyl group, a C6_6 alkyl group substituted with one or more hydroxyl groups and a C -6-NRERF alkylene group, in which RA, RB, identical or different, represent hydrogen or a CX-β alkyl group, or RA and RB together with the bridge nitrogen atom form a saturated, mono- or bicyclic 3-10 membered heterocyclic ring system, which may be at least monosubstituted with one or more C.sub.1-6 alkyl groups identical or different and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a ring member, Rc, RD, identical or different, represent a hydrogen atom, a C? _6 alkyl group, a -CO-O-C? _6 alkyl group, a C3_8 cycloalkyl group, a C? _6-C3_8 cycloalkyl group, a C? _6-C6_6 alkylene group, or an alkyl group C? _6 substituted with one or more hydroxyl groups, or R, RD together with the bridge nitrogen atom form a 3-10 membered heterocyclic ring system, mono or bicyclic, which may be at least monosubstituted with one or more substituents independently selected from the group consisting of C? _6 alkyl, a -CO-C? _6 alkyl group -CO-O-C C_6 alkyl, a -CO-NH-C alquilo_6 alkyl group, a -CS-NH-C alquilo_6 alkyl group, an oxo group, a C?-6 alkyl group substituted with one or more hydroxyl groups, an alkylene group C? -6-O-C? _6 alkyl and a group -CO-0-NH2 and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of the group? ring, and in which RE, RF, identical or different, represent hydrogen or a C? _6 alkyl group, or RE and RF together with the bridge nitrogen atom form a 3-10 membered heterocyclic ring system, mono or bicyclic, which may be at least monosubstituted with one or more C? _6 alkyl groups identical or different and / or which may contain at least one other heteroat omo selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring. Preferred aryl groups, which optionally can be at least monosubstituted, are phenyl and naphthyl. If one or more of the residues R3-R8 represents or comprises a heteroaryl group that is substituted with one or more, for example 1, 2, 3, 4 or 5, substituents, unless defined otherwise, each of the substituents can be independently selected from the group consisting of a halogen atom (for example F, Cl, Br, I), a linear or branched C ?_6 alkyl group, a 'C alco6 alkoxy group. linear or branched, a formyl group, a hydroxyl group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C6_6 alkyl group, a cyano group, a carboxyl group, a -CO-O-C6_6 alkyl group, a moiety -CO-NRARB-, a moiety -CO-NH-NRcRD-, a -S-alkyl group C? _6, a -SO-alkyl group C? -6, a group -S02-alkyl C? _6, a group C 1-6-S-C 1-6 -alkyl group, a C 1-6 -OC-6-SO-C 1-6 alkyl group, a C 1-6-S-2-C 1-6 alkyl-alkylene group, an alkyl group C? _6 substituted with one or more hydroxyl groups and a C? _6-NRERF alkylene group, in which RA, RB, identical or different, represent hydrogen or a C? _6 alkyl group, or RA and RB together with the atom of bridge nitrogen form a saturated 3-10 member heterocyclic ring system, mono or bicyclic, which may be at least monosubstituted with one or more C? _6 alkyl groups identical or different and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as ring member, Rc, RD , identical or different, represent a hydrogen atom, a C? _6 alkyl group, a -CO-O-C? _6 alkyl group, a C3_8 cycloalkyl group, a C3_6 alkylene group, a C3_8 cycloalkyl group, a C6_6-0 alkylene group, or a C6_6 alkyl group substituted with one or more hydroxyl groups, or Rc, RD together with Nitrogen atom bridge form a saturated, mono- or bicyclic 3-10 membered heterocyclic ring system, which may be at least monosubstituted with one or more substituents independently selected from the group consisting of C? -6 alkyl, a group -CO- alkyl C? _6, a -CO-O-C? -6 alkyl group, a -CO-NH-C? -6 alkyl group, a -CS-NH-C? _6 alkyl group, an oxo group, an alkyl group C? -6 substituted with one or more hydroxyl groups, an alkylene group C? -6-O-C? _6 alkyl and a group -CO-? H2 and / or which may contain at least one other heteroatom selected from the group consisting of nitrogen, oxygen and sulfur as a member of the ring, and in which RE, RF, identical or different, represent hydrogen or a C? _6 or RE and RF alkyl group together with the bridging nitrogen atom they form a 3-10 membered monocyclic or bicyclic heterocyclic ring system, which may be at least monosubstituted with one or more C? _6 alkyl groups identical or different and / or which may contain at least one other heteroatom selected from the group consisting of in nitrogen, oxygen and sulfur as a ring member.

The heteroatoms, which are present as ring members in the heteroaryl radical can be selected, unless otherwise defined, independently of the group consisting of nitrogen, oxygen and sulfur. Preferably a heteroaryl radical may comprise 1, 2 or 3 heteroatoms independently selected from the group consisting of N, 0 and S as ring members. Suitable heteroaryl groups, which may be optionally at least monosubstituted, may preferably be selected from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, quinolinyl, isoquinolinyl, benzo [1,2,5] -thiodiazolyl, benzo [b] thiophenyl, benzo [b] furanyl, imidazo [2, lb] thiazolyl, triazolyl and pyrazolyl, most preferably being selected from the group consisting of thienyl, benzo [1,2, 5] -thiodiazolyl, benzo [ b] thiophenyl, imidazo [2, lb] thiazolyl, triazolyl and pyrazolyl. If one or more of the residues R4-R8 represents or comprises an aliphatic group, such as an alkyl group, linear or branched, saturated or unsaturated, which is substituted with one or more, for example 1, 2, 3, 4 or 5 , substituents, unless otherwise defined, each substituent may be independently selected from the group consisting of in hydroxyl, fluorine, chlorine, bromine, branched or unbranched C 1 _ 4 alkoxy, branched or unbranched C 1 _ 4 perfluoroalkoxy, branched or unbranched C 1 _ 4 perfluoroalkyl, amino, carboxyl, amido, cyano, nitro, -S02NH 2, - CO-C C4alkyl, -SO-C ?4alkyl, -S02-C alquilo4alkyl, -NH-S02-C1-4alkyl, the C1-4 alkyl may be in each case branched or unbranched, and phenyl group, more preferably being selected from the group consisting of hydroxyl, F, Cl, Br, methoxy, ethoxy, CF3 and a phenyl group. Preferred linear or branched, saturated or unsaturated aliphatic groups, which may be substituted with one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl , sec-butyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethynyl, propenyl, propynyl, butenyl and butynyl. If any of the residues R4-R8 represents or comprises a linear or branched alkylene group, said alkylene group may be preferably selected from the group consisting of -methylene - (CH2) -, ethylene - (CH2-CH2) -, n-propylene - (CH2-CH2-CH2) - or isopropylene - (-C (CH3) 2) -.

Particularly preferred is a medicament comprising at least one substituted pyrazoline compound of general formula I, wherein R1 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of linear or branched C6-6 alkyl, linear or branched C6-6 alkoxy, F, Cl, Br, I, CH2F, CHF2, CF3, CN, OH, N02, - (CAD) -R ', SH, SR ", SOR', S02R ', NH2, NHR', NR'R", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR'R ", R' and R" representing each occurrence independently, a linear or branched C6-6 alkyl group, R2 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 selected substituents independently of the group consisting of straight or branched C6-6alkyl or straight or branched C6-6alkoxy, F, Cl, Br, I, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R ', SH, SR', SOR ', S02R', NH2, NHR ', NR'R', - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR 'R', R 'and R "representing for each occurrence independently, a linear or branched C? -6 alkyl group, R3 represents a saturated or unsaturated C3_8 cycloaliphatic group, said C3_8 cycloaliphatic group being optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of linear or branched C6-6alkyl or straight or branched C6-6alkoxy, OH, F, Cl, Br, I, CN, CH2F, CHF2, CF3 and oxo (= 0) and said cycloaliphatic group C3_8 contain 1, 2 or 3 heteroatoms independently selected from the group consisting of N, 0 and S as ring members, or R3 represents a residue -NRR5, R4 represents a hydrogen atom or a linear C6-6 alkyl group or branched, R5 represents a linear or branched C6-6 alkyl group; a remainder S02-R6; a C3_8 saturated or unsaturated cycloaliphatic group, said C3_8 cycloaliphatic group being optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, OH, F, Cl, Br, I, CN, CH2F, CHF2, CF3 and oxo (= 0) and said cycloaliphatic group C3_8 may contain 1 , 2 or 3 heteroatoms independently selected from the group consisting of N, 0 and S as ring members, and R6 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, F, Cl, Br, I, CH2F, CHF2, CF3, CN, OH, N0, - (C = 0) -R ', SH, SR ", SOR', S02R ', NH2, NHR', NR'R", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR'R ", R' and R" representing for each occurrence independently, a linear C? -6 alkyl group or branched, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or an N-oxide corresponding thereto, a corresponding salt thereof, or a corresponding solvate thereof.

In addition, a medicament is particularly preferred, comprising at least one compound of general formula I given below, wherein R1 represents a phenyl ring, which is monosubstituted with a halogen atom, preferably a chlorine atom, at its 4-position, R2 represents a phenyl ring, which is disubstituted with two halogen atoms, preferably chlorine atoms , in their positions 2 and 4, R3 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a morpholinyl group or a -NR4R5- moiety, R4 represents a hydrogen atom or a linear or branched C6-6 alkyl group, R5 represents a linear or branched C5-5 alkyl group, a S02-R6 moiety, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo piperazinyl, a morpholinyl group, a triazolyl group, each of the heterocyclic rings can be substituted with one or more identical or different C? _6 alkyl groups, or a -S02-R6 residue, and R6 represents a phenyl group which is optionally substituted with one or more C? _6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof or a corresponding solvate thereof. More preferred is a medicament comprising at least one substituted pyrazoline compound selected from the group consisting of: N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4, 5- dihydro-lH-pyrazole-3-carboxamide, [1, 2,4] -triazol-4-yl-amide of 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole- 3-carboxylic acid 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole acid (4-methyl-piperazin-1-yl) -amide -3-carboxylic acid, 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid diethylamide, [5- (4- chloro-phenyl) -l- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazol-3-yl] -piperidine-1-yl-methanone, N- [5- (4-chloro- phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carbonyl] -4-methylphenylsufonamide, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. The medicament of the invention may preferably also comprise any of the pyrazoline compounds of the invention or combinations of at least two of these pyrazoline compounds provided above. Said medicament may also comprise any combination of one or more of the substituted pyrazoline compounds of the general formula I provided above, stereoisomers thereof, corresponding N-oxides thereof, physiologically acceptable salts thereof or physiologically acceptable solvates of the same. same.

Preferably, said medicament is suitable for the modulation (regulation) of cannabinoid receptors, preferably cannabinoid type 1 receptors (CBi), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the system cardiovascular disease, endocrine system disorders, respiratory system disorders, gastrointestinal tract disorders or reproductive disorders. In a particularly preferred manner, said medicament is suitable for the prophylaxis and / or treatment of psychosis. Also in a particularly preferred form, said medicament is suitable for the prophylaxis and / or treatment of eating disorders, preferably bulimia, anorexia, cachexia, obesity and / or type II diabetes mellitus (diabetes mellitus not dependent on insulin). , more preferably obesity. The medicament of the invention also appears to be active in the prophylaxis and / or treatment of appetite disorders, for example the pyrazoline compounds of general formula I also reduce the desire for sweets. Also in a particularly preferred manner, said medicament is suitable for prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer. In a particularly preferred manner, said medicament is suitable for the prophylaxis and / or treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, drug abuse and / or addiction and / or abuse and / or addiction. medications, preferably drug abuse and / or addiction and / or nicotine abuse and / or addiction. Medications and / or drugs that are often the subject of misuse include opiates, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines.

The medicament is also suitable for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (eg osteoporosis associated with a genetic predisposition, deficiency of sex hormones, or aging), associated bone disease. with cancer or Paget's bone disease; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, brain trauma, stroke, panic attacks, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Aimer's disease, Raynaud's disease, tremor disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, drug-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, plaques sclerotics, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or to potentiate the analgesic effect of narcotic and non-narcotic analgesics, or to influence intestinal transit.

Another aspect of the present invention is the use of at least one substituted pyrazoline compound of the general formula I given above as a suitable active substance, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or distereomers, in any mixture ratio, or a corresponding N-oxide thereof, or a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicine for the modulation of cannabinoid receptors, preferably of type 1 cannabinoid receptors (CBi), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system , disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. Particularly preferred is the use of at least one of the respective pyrazoline compounds, optionally in the form of one of the stereoisomers, preferably enantiomers or distereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of psychosis. Also particularly preferred is the use of at least one of the respective pyrazoline compounds, optionally in the form of one of the stereoisomers, preferably enantiomers or distereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for prophylaxis and / or treatment of disorders of food intake, preferably bulimia, anorexia, cachexia, obesity and / or type II diabetes mellitus (diabetes mellitus not dependent on insulin), more preferably obesity. Also particularly preferred is the use of at least one of the respective pyrazoline compounds, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for prophylaxis and / or cancer treatment, preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, cancer lung, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer. Also particularly preferred is the use of at least one of the respective pyrazoline compounds, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for prophylaxis and / or treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, abuse and / or drug addiction and / or drug abuse and / or addiction, preferably drug abuse and / or addiction and / or the abuse and / or nicotine addiction. Medications / drugs that are often the subject of misuse include opiates, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines. Also preferred is the use of at least one of the respective pyrazoline compounds, optionally in the form of one of the stereoisomers, preferably enantiomers or distereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixture ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (e.g. osteoporosis associated with a genetic predisposition, deficiency of sex hormones, or aging), bone disease associated with cancer or Paget's disease of bone, - schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, head trauma, brain trauma, stroke , panic attacks, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremor disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, disorders bipolar disorders, drug-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain or to potentiate the analgesic effect of narcotic analgesics and no narcotics, or to influence intestinal transit. The medicament according to the present invention may be in any form suitable for application in humans and / or animals, preferably in humans including infants, children and adults, and may be produced by conventional methods known to those skilled in the art. The composition of the medication may vary depending on the route of administration. The medicament of the present invention can be administered for example parenterally in combination with conventional injectable liquid carriers such as water or suitable alcohols. In such injectable compositions can be included conventional pharmaceutical excipients for injection, such as stabilizing agents, solubilizing agents and buffers. These drugs can be injected, for example, intramuscularly, intraperitoneally or intravenously.

The medicaments according to the present invention can also be formulated in orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional components such as binders, fillers, lubricants and acceptable wetting agents. The compositions may take any convenient form, such as tablets, granules, capsules, dragees, aqueous or oily solutions, suspensions, emulsions or dry powder forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate release or delayed. The liquid oral forms for administration may also contain certain additives such as sweeteners, flavors, preservatives and emulsifying agents. Non-aqueous liquid compositions for oral administration containing edible oils can also be formulated. Such liquid compositions can conveniently be encapsulated, for example, in gelatin capsules in a unit dosage amount.

The compositions of the present invention can also be administered topically or by means of a suppository. The daily dosage for humans and animals can vary depending on factors that are based on the respective species or other factors such as age, sex, weight or degree of disease, and so on. The daily dosage for humans may preferably be in the range of 1 to 2000, preferably 1 to 1500 and more preferably 1 to 1000 mg of active substance to be administered during one or more doses per day.

Pharmacological Methods I. In vitro determination of affinity for CB1 / CB2 receptors The in vitro determination of the affinity of the substituted pyrazoline compounds of the invention for the CB? / CB2 receptors is carried out as described in the Ruth A publication. Ross, Heather C. Brockie et al., "Agonist-inverse agonist characterization at CBi and CB2 cannabinoid receptors of L-759633, L759656 and AM630", British Journal of Pharmacology, 126, 665-672, (1999), using the transfected human CBi and CB2 receptors from Receptor Biology, Inc. The radioligand used for the two receptors is [3H] -CP55940. The respective parts of the description are incorporated herein by reference and form a part of the present description.

II. In vivo bioassay system for the determination of cannabinoid activity Mouse tetrada model It is known that substances with affinity for cannabinoid receptors produce a wide range of pharmacological effects. It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice produces analgesia, hypothermia, sedation and catalepsy. Individually, none of these effects can be considered proof that a test substance has an affinity for cannabinoid receptors, since all these effects are common for various classes of centrally active agents. However, the substances that show all these effects, that is, the substances that are active in this model called the tetrada model are considered substances with affinity for the receptors of cannabinoids It has also been shown that cannabinoid receptor antagonists are very effective in blocking the effects of a cannabinoid agonist in the mouse tetrada model. The tetrada model is described, for example, in the publication of A. C. Howlett et al, International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors, Pharmacol Rev 54, 161-202, 2002 and David R. Compton et al., "In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A): Inhibition of Tetrahydrocannabinol-induced Responses and Apparent Agonist Activity", J. Pharmacol. Exp. Ther. 277, 2, 586-594, 1996. The corresponding parts of the description are incorporated herein by reference.

Materials and Methods In all the experiments described below, male MRI mice with a weight of 20-30 g are used (Harán, Barcelona, Spain). Prior to testing in the behavioral procedures provided below, the mice are acclimated to the experimental site. Pre-treatment control values are determined for platelet analgesia latency hot (in seconds), rectal temperature, sedation and catalepsy. To determine the agonist activity of the substance to be tested, mice receive intravenous injections of the substance to be tested or of the vehicle alone. Fifteen minutes after the injection, the latency of the hot plate analgesia is measured. Rectal temperature, sedation and catalepsy are measured 20 minutes after the injection. To determine the antagonist activity, a procedure identical to that used for the determination of the agonist effects is used, but with the difference that the substance whose antagonist activity is to be evaluated is injected 5 minutes before the intravenous injection of 1.25 mg / kg of Win-55,212, a known cannabinoid receptor agonist.

Hot plate analgesia Hot plate analgesia is determined according to the method described in Woolfe D. et al. "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307, 1944. The respective description is incorporated herein by reference and forms part of the present disclosure.

The mice are put on a hot plate (Harvard Analgesimeter) at 55 ± 0.5aC until they show a painful sensation when they lick their legs or jump and the moment in which these sensations occur is recorded. This reading is considered the basal value (B). The maximum time limit during which the mice are left on the hot plate in the absence of any painful response is 40 seconds to prevent the appearance of skin lesions. This period is called the time limit (PC). Fifteen minutes after the administration of the substance to be tested, the mice are put back on the hot plate and the procedure described above is repeated. This period is called post-treatment reading (PT). The degree of analgesia is calculated from the formula:% Analgesia MPE = (PT-B) / (PC-B) x 100 MPE = maximum possible effect.

Determination of Sedation and Ataxia Sedation and ataxia are determined according to the method described in Desmet L. K. et al, "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975. The description respective is incorporated herein by reference and forms part of the present description. The chosen scoring system is 0: without ataxia; 1: doubtful; 2: clear calm and quiet; 3: pronounced ataxia; both before and after the treatment. The percentage of sedation is determined according to the formula:% sedation = arithmetic mean / 3 x 100 Hypothermia: Hypothermia is determined according to the method described in David R. Compton et al. "In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A) Inhibition of Tetrahydrocannabinol-induced Responses and Apparent Agonist Activity", J. Pharmacol Exp Ther. 277, 2, 586-594, 1996. The respective description is incorporated herein by reference and forms part of the present disclosure. The basal rectal temperatures are determined with a thermometer (Yello Springs Instruments Co., Panlabs) and a thermistor probe inserted to a depth of 25 mm before the administration of the substance to be tested. The rectal temperature is measured again 20 minutes after the administration of the substances to be tested. The temperature difference for each animal is calculated, considering that they represent activity differences = 2aC.

Catalepsy: Catalepsy is determined according to the method described in Alpermann H.G. et al. "Pharmacological effects of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is incorporated herein by reference and forms part of the present description. The cataleptic effect of the substance to be tested is evaluated according to the duration of the catalepsy by placing the animals head-down with their legs on top of the block of wood. The scoring system chosen is: Catalepsy during: more than 60 seconds = 6; 50-60 seconds = 5, 40-50 seconds = 4, 30-40 seconds = 3, 20-30 seconds = 2, 5-10 seconds = 1, and less than 5 seconds = 0.

The percentage of catalepsy is determined according to the following formula:% catalepsy = arithmetic mean / 6 x 100 III. In vivo assay of anti-obesity activity In vivo assays for the anti-obesity activity of the pyrazoline compounds of the invention are carried out as described in the publication by G. Colombo et al., "Appetite Suppression and Weigth Loss after the Cannabinoid Antagonist SR 141716"; Life Sciences, 63 (8), 113-117, (1998). The respective part of the description is incorporated herein by reference and forms part of the present description.

IV. In vivo assay of the antidepressant activity In vivo tests of the antidepressant activity of the pyrazoline compounds of the invention in the desperation test in water are carried out as described in the publication of E.T. Tzavara et al., "The CBl receptor antagonist SR 141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions"; Br. J. Pharmacol., 2003, 138 (4): 544: 53.

Description is incorporated herein by reference and forms part of the present disclosure. The present invention is illustrated below with the help of examples. These illustrations are only provided by way of example and do not limit the general spirit of the present invention.

Examples: Example 1 N-Piperidinyl-5- (4-chlorophenyl) -l- (2/4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carboxamide a) 4- (4-chlorophenyl) acid - 2-oxo-3-butenoic In a three-necked flask p-chlorobenzaldehyde (13.3 g, 95 mmol) and ethyl pyruvate (10 g, 86 mmol) were dissolved in 150 mL of absolute ethanol. The solution was cooled with ice at 02C and a solution was added dropwise.

NaOH solution (3.8 g in 45 ml of water) maintaining the temperature below or equal to 10aC, so that a yellow-orange precipitate formed. The reaction mixture was stirred for 1 hour at 02C and for an additional 1.5 hours at room temperature (approximately 252C). After this, the reaction mixture was cooled to about 52 ° C and the insoluble sodium salt of 4- (4-chlorophenyl) -2-oxo-3-butenoic acid was isolated by filtration. The filtrate was left in the refrigerator overnight, so that more precipitate was formed, which was removed by filtration, combined with the first fraction of the salt and washed with diethyl ether. Then, the sodium salt of 4- (4-chlorophenyl) -2-oxo-3-butenoic acid was treated with a 2 N HCl solution, stirred for a few minutes and 4- (4-chlorophenyl) -2 acid was removed. -oxo-3-butenoic solid by filtration and dried to give 12.7 g of the desired product (70% of theoretical yield). IR (KBr, cm "1): 3500-2500, 1719.3, 1696.5, 1603.4, 1587.8, 1081.9 XH NMR (CDC13, d): 7.4 (d, J = 8 , 4 Hz, 2H), 7.5 (d, J = 16.1 Hz, 1H), 7.6 (d, J = 8.4 Hz, 2H), 8.1 (d, J = 16.1 Hz, ÍH). b) 5- (4-chlorophenyl) -l- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxylic acid 4- (4-Chlorophenyl) -2-oxo-3-butenoic acid obtained according to step a) (12.6 g, 60 mmol), 2,4-dichlorophenylhydrazine hydrochloride (12.8 g, 60 mmol) was mixed. and glacial acetic acid (200 ml) in a nitrogen atmosphere and heated to reflux for 4 hours, cooled to room temperature (approximately 252C) and introduced into ice-cold water, whereby a thick mass was obtained, which was extracted with methylene chloride. The combined methylene chloride fractions were washed with water, dried with sodium sulfate, filtered and evaporated to dryness to give a pale yellow solid (12.7 g, 57% of theory). IR (KBr, cm "1): 3200-2200, 1668.4, 1458, 1251.4, 1104.8.

X H NMR (CDCl 3, d): 3.3 (dd, 1H), 3.7 (dd, 1H), 5.9 (dd, 1H), 7.09-7.25 (m, 7H). (c) 5- (4-chlorophenyl) -l- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid chloride Under a nitrogen atmosphere, 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid (2.5 g, 6.8 mmol) obtained was dissolved. according to step (b) in 4 ml of thionyl chloride and heated to reflux for 2.5 hours. The excess thionyl chloride was removed from the reaction mixture under reduced pressure and the resulting crude residue (2.6 g) was used without any further purification. IR (KBr, crtf1): 1732.3, 1700, 1533.3, 1478.1, 1212.9, 826.6. d) N-piperidinyl-5- (4-chlorophenyl) -l- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide [this compound can also be referred to as piperidin-1-ylamide of 5- (4 -chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid or 1- (2, -dichlorophenyl) -5- (4-chlorophenyl) -4,5-dihydro -N-piperidin-1-yl) -lH-pyrazole-3-carboxamide] In a nitrogen atmosphere, N-aminopiperidine (0.6 ml, 5.6 mmol) and triethylamine (4 ml) were dissolved in methylene chloride (25 ml). The resulting mixture was cooled with ice to 0 ° C and a solution of 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazole-3-carboxylic acid chloride solution was added dropwise. obtained in step (c) in methylene chloride (15 ml). The resulting reaction mixture was stirred at room temperature (approximately 252C) during one night. After this, the reaction mixture was washed with water, followed by a saturated aqueous solution of sodium bicarbonate and then again with water, dried over sodium sulfate, filtered and evaporated to dryness in a rotary evaporator. The resulting crude solid was crystallized from ethanol. The crystallized solid was removed by filtration and the mother liquor was concentrated to produce a second crystallized product fraction. The two fractions were combined to give a total amount of 1.7 g (57% of theory) of N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole -3-carboxamide having a melting point of 183-1862C. IR (KBr, cm "1): 3222.9, 2934.9, 1647.4, 1474.7, 1268.3, 815.6 E NMR (CDC13, d) 1.4 (m, 2H), 1 , 7 (m, 4H), 2.8 (m, 4H), 3.3 (dd, J = 6.1 and 18.3 Hz, lH), 3.7 (dd, J = 12.5 and 18) , 3 Hz, HH), 5.7 (dd, J = 6.1 and 12.5 Hz, HH), 7.0-7.2 (m, 6H), 7.4 (s, 1H). The compounds according to the following examples 2-6 have been prepared in a manner analogous to the procedure described in Example 1. Example 2 [l, 2,4] Triazol-4-yl amide of 5- (4-chloro-phenyl) acid -l- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid Melting point: 134-138aC IR (KBr, cm "1): 3448, 1686, 1477, 1243, 1091, 821. XH NMR (CDC13, d): 3.1 (dd, J = 6.2 and 17, 9 Hz, HH), 3.7 (dd, J = 12.3 and 17.9 Hz, HH), 5.9 (dd, J = 6.2 and 12.3 Hz, HH), 7.2- 7.5 (, 7H), 8.7 (s, 2H), 12.0 (sa, ÍH).

Example 3: 5- (4-Chloro-phenyl) -l- (2,4-dichloro-phenyl) -4,5-dihydro-lH (4-methyl-? Iperazin-1-yl) -amide hydrochloride -pyrazole-3-carboxylic melting point: 150-155SC IR (KBr, cm "1): 3433, 1685, 1477, 1296, 1246, 1088, 1014, 825. X. NMR (CDCl 3, d): 2, 7 (d, J = 4.2 Hz, 3H), 3.0-3.4 (m, 9H), 3.6 (dd, J = 11.9 and 17.9 Hz, ÍH), 5.8 (dd, J = 5.5 and 11.9 Hz, 1H), 7.1 (d, J = 8.4 Hz, 2H), 7.25 (2d, J = 8.4 and 8.7 Hz, 3H), 7.4 (d, J = 2.2 Hz, ÍH), 7.5 (d, J = 8.7 Hz, ÍH), 9.8 (s, lH), 11.2 (s) .

Example 4 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole-3-carboxylic acid diethylamide This compound was obtained in the form of an oil. IR (film, cm "1): 2974, 1621, 1471, 1274, 1092, 820.

XH NMR (CDCl 3, d): 1.2 (m, 6H), 3.3-3.9 (m, 6H), 5.6 (dd, J = 5.8 and 11.7 Hz, ÍH), 7-7.25 (, 7H).

Example 5: 15- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazol-3-yl] -piperidin-1-yl-methanone Melting Point : 105-1102C. IR (KBr, c "1): 2934, 1622, 1470, 1446, 1266, 1010, 817. 4 1 NMR (CDCl 3, d): 1.7 (m, 6H), 3.4 (dd, J = 5, 7 and 17.9 Hz, ÍH), 3.7 (m, 3H), 3.9 (m, 2H), 5.6 (dd, J = 6.1 and 11.9 Hz, ÍH), 7- 7.25 (m, 7H).

Example 6: N- [5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carbonyl] -4-methyl-phenylsulfonamide This compound it was obtained in the form of an amorphous solid. IR (KBr, cm "1): 1697, 1481, 1436, 1340, 1169, 1074, 853. XH NMR (CDCl3, d): 2.4 (s, 3H), 3.2 (dd, J = 6, 6 and 18.3 Hz, ÍH), 3.6 (dd, J = 12.8 and 18.3 Hz, lH), 5.8 (dd, J = 6.6 and 12.8 Hz, ÍH), 7 (d, J = 8.2 Hz, 2H), 7.2 (s, ÍH), 7.3-7.4 (m, 6H), 8 (d, J = 8.1 Hz, 2H), 9 (s, 1H).

Example 7: N-Piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide N-oxide. In an atmosphere of nitrogen gas as an inert atmosphere, N- was dissolved. piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide (0.15 g, 332 mmol) in 7 ml of dichloromethane. The resulting solution was cooled with ice to 02C and m-chloroperbenzoic acid (0.204 g, 0.83 mmol) was added in several portions. After shaking for 15 minutes a control by thin layer chromatography showed that no starting material remained. After a saturated solution of sodium bicarbonate was slowly added, the organic phase was separated, washed with water, dried over sodium sulfate and filtered. The filtered solution was evaporated to dryness and the crude product was purified by column chromatography, yielding 78 mg (50% of theoretical yield) of N-piperidinyl-5- (4-chlorophenyl) -1- (2, 4-dichlorophenyl) -4,5-dihydropyrazol-3-carboxamide as a white solid having a melting point of 115-120 ° C. IR (KBr, cm "1): 3202, 1678, 1654, 1474, 1309, 1107. XH NMR (CDC13, d): 1.6 (m, 2H), 1.8-2.0 (m, 2H) , 2.55 (m, 2H), 3.3 (dd, J = 6.3 Hz and 18.2 Hz, ÍH), 3.7 (m, 3H), 5.8 (dd, J = 6, 3 Hz and 12.5 Hz, ÍH), 7.0-7.3 (m, 7H), 8.5 (s, ÍH).

Pharmacological Data I. In vitro determination of affinity for receptors The affinity of the substituted pyrazoline compounds of the invention for CB? / CB2 receptors was determined as described above. Table I below shows some of the values obtained: Table I: As can be seen from the values provided in Table 1, the pyrazoline compounds of the invention are particularly suitable for regulating the CBi receptor.

II. In vivo bioassay system for the determination of cannabinoid activity The determination of cannabinoid activity in vivo was determined as described above. In Table II presented below some of the obtained values are provided: Table II: í.v. = intravenous A: Hot plate assay B: Hypothermia C: Catalepsy D: Sedation As can be seen from the values provided in Table II, the pyrazoline compounds of the invention show an antagonistic effect.

III. In vivo assays of anti-obesity activity In vivo assays for anti-obesity activity were performed as described above, treating four different groups of 10 rats each as follows: Group I: The group was treated with vehicle, particularly gum arabic (5% by weight) in water.

Group II: The second group of rats was treated with the compound of the invention N-piperidinyl-5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydropyrazole-3-carboxamide according to the example 1. Said compound was administered intraperitoneally to rats for a period of 14 days in a daily dose of 10 mg / kg of body weight.

Group III: The third group of rats was treated with amphetamine, an active substance that is known to reduce appetite. Said compound was administered intraperitoneally to the rats for a period of 14 days in a daily dose of 5 mg / kg of body weight. As can be seen in figure 1, the body weight decreases due to the administration of the compound of the invention according to example 1 and this effect is also observed after the end of treatment. Figure 2 shows the reduction of food intake due to the administration of the compound of the invention according to example 1.

IV. In vivo test of the antidepressant activity The in vivo tests of the antidepressant activity of the pyrazoline compounds of the invention in the desperation test in water were carried out as described above. In particular, the compound according to example 1 exhibited positive effects with respect to the immobility time and the time of movements with difficulty.

Claims (1)

1. CLAIMS 1. - Substituted pyrazoline compounds of general formula I wherein R1 represents an optionally at least monosubstituted phenyl group; R 2 represents an optionally at least monosubstituted phenyl group; R3 represents a cycloaliphatic group optionally containing at least one heteroatom as ring member, optionally at least monosubstituted, saturated or unsaturated, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted; or R3 represents an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents a -NR4R5- moiety, R4 and R5, identical or different, represent an atom of hydrogen; an aliphatic radical optionally at least monosubstituted, unbranched or branched, saturated or unsaturated; a cycloaliphatic group optionally containing at least one heteroatom as ring member, optionally at least monosubstituted, saturated or unsaturated, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a linear or branched alkylene group, a -S02-R6- moiety or a rest -NR7R8-, with the provisos that R4 and R5 do not represent at the same time a hydrogen atom, and if one of the residues R4 and R5 represents a hydrogen atom or an alkyl group, which is optionally at least monosubstituted with a alkoxyl group, a group alkoxyalkoxy, a halogen atom or a phenyl group, the other of these residues R4 and R5 does not represent a pyrid-2-yl group, which is optionally monosubstituted in the 5-position; a pyrid-5-yl group; which is optionally monosubstituted in the 2-position; a pyrimid-5-yl group; which is optionally monosubstituted in the 2-position; a pyridaz-3-yl group; which is optionally monosubstituted in the 6-position; a pyrazin-5-yl group; which is optionally monosubstituted in the 2-position; a thien-2-yl group; which is optionally monosubstituted in the 5-position; a thien-2-yl group; which is optionally at least monosubstituted in the 4-position; a benzyl group; which is optionally monosubstituted at the 4-position of the ring; a phenethyl group; which is optionally monosubstituted at the 4-position of the ring; an optionally mono, di or trisubstituted phenyl group; a disubstituted phenyl group, wherein the two substituents together form a chain -OCH20-, -OCH2CH20- or -CH2CH20-, which is optionally substituted with one or more halogen atoms or one or two methyl groups; a -NH-phenyl moiety, wherein the phenyl group may be monosubstituted at the 4-position, and if one of the residues R4 and R5 represents an alkynyl group, the other of these residues R4 and R5 does not represent a phenyl group, which is optionally substituted at the 4-position, and if one of the residues R4 and R5 represents a hydrogen atom or a linear or branched aliphatic radical, saturated or unsaturated, substituted or unsubstituted, the other of these residues R4 and R5 does not represent a substituted or unsubstituted thiazole group or a substituted or unsubstituted [1, 3, 4] thiadiazole group; R6 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted; a cycloaliphatic group optionally containing at least one heteroatom as ring member; saturated or unsaturated; optionally at least monosubstituted; which may be condensed with a mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system and / or linked through a linear or branched alkylene group, R and R, identical or different, represent a hydrogen atom; a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted; a cycloaliphatic group optionally containing at least a heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a straight or branched alkylene group, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof , or a corresponding solvate thereof. 2. - Compounds according to claim 1, characterized in that R1 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxyl group , a halogen atom, CH2F, CHF2, CF3, C ?, OH,? 02, - (C = 0) -R \ SH, SR ', SOR', S02R ',? H2,? HR', NR'R ", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR' R", R 'and R "representing each substituent, independently, C-alkyl ? -6 linear or branched, preferably R1 represents a phenyl group, which is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R1 represents a phenyl group, which is monosubstituted with a chlorine atom in position 4. 3. - Compounds according to claim 1 or 2, characterized in that R 2 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C 1-6 alkyl group, a linear C 1-6 alkoxyl group or branched, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R \ SH, SR ', SOR', S02R ', NH2, NHR',? R'R " , - (C = 0) -? H2, - (C = 0) -? HR 'and - (C = 0) -? R' R ", optionally representing R 'and R" for each substituent, independently, C-alkyl ? 6 linear or branched, preferably R2 represents a phenyl group which is optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R2 represents a phenyl group, which is disubstituted with two chlorine atoms in their positions 2 and 4. 4. - Compounds according to one or more of claims 1-3, characterized in that R3 represents a C3_8 cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be condensed with a mono- or polycyclic ring optionally at least monosubstituted, or R represents a 5- or 6-membered aryl or heteroaryl group, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted, or R3 represents a moiety -NRR5-, preferably R3 represents a C3_8 cycloaliphatic group optionally containing one or more nitrogen atoms as ring members, saturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents a residue -NRR5-, more preferably R3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, each of these groups may be substituted with one or more C? _6 alkyl groups, or R3 represents a -NR4R5- residue. 5. - Compounds according to one or more of claims 1-4, characterized in that R4 and R5, identical or different, represent a hydrogen atom; an aliphatic radical Ca-6, branched or unbranched, saturated or unsaturated, optionally at least monosubstituted; a C3_8 cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a methylene group (-CH2) or an ethylene group (-CH2-CH2) -; a residue -S02-R6-; or a residue -NR7R8-, preferably one of these residues R4 and R5 represents a hydrogen atom and the other of these residues R4 and R5 represents a C3_8 cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted; or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; a residue -S02-R-; or a moiety -NR7R8- or R4 and R5, identical or different, each represents a C6_6 alkyl group, more preferably one of these residues R4 and R5 represents a hydrogen atom and the other of these residues R4 and R5 represents a optionally at least monosubstituted pyrrolidinyl group; an optionally at least monosubstituted piperidinyl group; an optionally at least monosubstituted piperazinyl group; an optionally at least monosubstituted triazolyl group; a remainder - S02-R6-; or a residue -NR7R8-, or R4 and R5, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tertiary group -butyl. 6. - Compounds according to one or more of claims 1-5, characterized in that R6 represents a linear or branched, saturated or unsaturated C6-6 aliphatic group, optionally at least monosubstituted; a C3_8 cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be condensed with a mono or polycyclic ring system; or an optionally at least monosubstituted, 5 or 6 membered aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system and / or linked through a methylene (-CH2-) or ethylene (-CH2-) group CH) -, preferably R6 represents a C6_6 alkyl group, an optionally at least monosubstituted saturated cycloaliphatic group, which may be fused with a mono or polycyclic ring system; or a phenyl group, which is optionally substituted with one or more C alquilo alkyl groups 7. - Compounds according to one or more of claims 1-6, characterized in that R7 and R8, identical or different, represent a hydrogen atom; a branched or unbranched, saturated or unsaturated C6-6 aliphatic radical, optionally at least monosubstituted; a C3_8 cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, of 5 or 6 members, which may be condensed with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a methylene group (-CH2-) or ethylene (-CH2-CH2) -, preferably R7 and R8, identical or different, represent a hydrogen atom or a C? -6 alkyl radical. ; .- Compounds of general formula I according to one or more of the wherein R1 represents a phenyl ring, which is monosubstituted with a halogen atom, preferably a chlorine atom, in its 4-position, R2 represents a phenyl ring, which is disubstituted with two halogen atoms, preferably chlorine atoms , in their positions 2 and 4, R3 represents a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a homo-piperazinyl group; a morpholinyl group; or a rest -NR4R5-, R4 represents a hydrogen atom or a linear or branched C6-6 alkyl group, R5 represents a linear or branched C6-6 alkyl group; a remainder S02-R6; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a homo-piperazinyl group; a morpholinyl group; a triazolyl group, each of the heterocyclic rings may be substituted with one or more identical or different C? -6 alkyl groups, and R6 represents a phenyl group which is optionally substituted with one or more C? _6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or an N corresponding oxide thereof, a corresponding salt thereof or a corresponding solvate thereof. 9. - Compounds according to one or more of claims 1 to 8, selected from the group consisting of: N-piperidinyl-5- (4-chloro-phenyl) -l- (2,4-dichlorophenyl) -4,5-dihydro- lH-pyrazole-3-carboxamide, [1, 2,4] -triazol-4-yl-amide of 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole- 3-carboxylic acid 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-1H-pyrazole acid (4-methyl-piperazin-1-yl) -amide -3-carboxylic acid, 5- (4-chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid diethylamide, [5- (4- chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazol-3-yl] -piperidine-1-yl-methanone, N- [5- (4-chloro- phenyl) -l- (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carbonyl] -4-methylphenylsufonamide, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. 10. - Process for the preparation of substituted pyrazoline compounds of general formula I according to one or more of claims 1 to 9, characterized in that at least one benzaldehyde compound of general formula II (II) wherein R1 has the meaning according to one or more of claims 1-9, it is reacted with a compound of pyruvate of general formula (III) (III) in which G represents an OR group with R being a C? -6 branched or unbranched alkyl radical or G represents a group 0"K with K being a cation, to give a compound of general formula (IV) (IV) wherein R1 has the meaning given above, which is optionally isolated and / or optionally purified, and which is reacting with an optionally substituted phenylhydrazine of general formula (V) (v) or a corresponding salt thereof, wherein R2 has the meaning according to one or more of claims 1-9, in an inert atmosphere, to give a compound of general formula (VI) (SAW) wherein R1 and R2 have the meanings given above, which is optionally isolated and / or optionally purified, and which is optionally converted, in an inert atmosphere, to a compound of general formula (VII) by means of the reaction with an activating agent (VII) wherein the substituents R1 and R2 have the meanings given above and A represents a leaving group, optionally isolating and / or optionally purifying said compound, and reacting at least one compound of general formula (VI) with a compound of general formula R3H, wherein R3 represents a moiety -NR4R5-, R4 and R5 having the meanings according to one or more of claims 1-9, in an inert atmosphere, to give a substituted pyrazoline compound of general formula I, wherein R3 represents a residue -NR4R5-, and / or at least one compound of formula is reacted (VII) with a compound of the general formula R3H, wherein R3 has the meaning according to one or more of claims 1-9, in an inert atmosphere, to give a compound of the general formula (I) according to one or more of claims 1-9, which is optionally isolated and / or optionally purified. 11. - A medicament comprising at least one substituted pyrazoline compound of general formula I, wherein R represents an optionally at least monosubstituted phenyl group, R 2 represents an optionally at least monosubstituted phenyl group, R 3 represents a cycloaliphatic group optionally containing at least one heteroatom as ring member, optionally at least monosubstituted, saturated or unsaturated, which may be fused with a mono or polycyclic ring system optionally at less monosubstituted, or R3 represents an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents an identical or different moiety -NRR5-, R4 and R5, they represent a hydrogen atom; an aliphatic radical optionally at least monosubstituted, unbranched or branched, saturated or unsaturated; a cycloaliphatic group optionally containing at least one heteroatom as ring member, optionally at least monosubstituted, saturated or unsaturated, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted and / or linked through a linear or branched alkylene group; a residue -S02-R6-; or a -NR7R8- moiety, R6 represents a linear or branched, saturated or unsaturated aliphatic group, optionally at least monosubstituted; a cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked through a linear or branched alkylene group, R7 and R8, identical or different, represent a hydrogen atom; a branched or unbranched, saturated or unsaturated aliphatic radical, optionally at least monosubstituted; a cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted aryl or heteroaryl group, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted and / or linked through a linear or branched alkylene group, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof. 12. - Drug according to claim 11, characterized in that R1 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxyl group , a halogen atom, CHF, CHF2, CF3, CN, OH, N02, - (C = 0) -R \ SH, SR ', SOR', S02R ', NH2, NHR', NR'R ', - ( C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR' R ", R 'and R" representing each substituent, independently, linear or branched C? -6 alkyl, preferably R1 represents a phenyl group, which is optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R1 represents a phenyl group, which is monosubstituted with a chlorine atom in the 4-position. 13. - Drug according to claim 11 or 12, characterized in that R2 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a linear or branched C? -6 alkyl group, a C? 6 linear or branched, a halogen atom, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) ~ R ', SH, SR', SOR ', S02R', NH2, NHR ', NR' R ", - (C = 0) -NH2, - (C = 0) -NHR 'and - (C = 0) -NR' R", optionally representing R 'and R "for each substituent, independently, C-alkyl? -6 linear or branched, preferably R2 represents a phenyl group which is optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, more preferably R2 represents a phenyl group, which is disubstituted with two chlorine atoms in their positions 2 and 4. 14. - Drug according to one or more of claims 11-13, characterized in that R3 represents a C3_8 cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system, or R3 represents a 5 or 6 membered aryl or heteroaryl group, optionally at least monosubstituted , which may be condensed with a mono- or polycyclic ring system optionally at least monosubstituted, or R3 represents a moiety -NR4R5-, preferably R3 represents a C3_8 cycloaliphatic group optionally containing one or more nitrogen atoms as ring members, saturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system optionally at least monosubstituted, or R3 represents a -NR4R5- moiety, more preferably R3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, each of these groups may be substituted with one or more C? _6 alkyl groups, or R3 represents a residue -NR4R5-. 15. - Drug according to one or more of claims 11-14, characterized in that R4 and R5, identical or different, represent a hydrogen atom; an aliphatic radical C? _6, branched or unbranched, saturated or unsaturated, optionally at least monosubstituted; a C3-s cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a methylene group (-CH) or an ethylene group (-CH2-CH2) -; a residue -S02-R6-; or a residue -NR7R8-, preferably one of these residues R4 and R5 represents a hydrogen atom and the other of these residues R4 and R5 represents a C3-8 cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted; or an optionally at least monosubstituted 5 or 6-membered aryl or heteroaryl group, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; a residue -S02-R6-; or a rest -NR7R8-, or R4 and R5, identical or different, represent each a C? _6 alkyl group, more preferably one of these residues R4 and R5 represents a hydrogen atom and the other of these residues R4 and R5 represents an optionally at least monosubstituted pyrrolidinyl group; an optionally at least monosubstituted piperidinyl group; an optionally at least monosubstituted piperazinyl group; an optionally at least monosubstituted triazolyl group; a residue -S02-R6-; or a residue -NR7R8-, or R4 and R5, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tertiary group -butyl 16. Medicament according to one or more of claims 11-15, characterized in that R6 represents a linear or branched, saturated or unsaturated, C6-6 aliphatic group, optionally at least monosubstituted; a C3-8 cycloaliphatic group optionally containing at least one heteroatom as ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with a mono or polycyclic ring system; or an optionally at least monosubstituted, 5- or 6-membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system and / or linked through a methylene group (-CH2-) or ethylene (-CH2-CH2) -, preferably R6 represents a C6_6 alkyl group; an optionally at least monosubstituted saturated cycloaliphatic group, which may be fused with a mono or polycyclic ring system; or a phenyl group, which is optionally substituted with one or more C alquilo alkyl groups 17. - Drug according to one or more of claims 11-16, characterized in that R7 and R8, identical or different, represent a hydrogen atom; a branched or unbranched, saturated or unsaturated C? -6 aliphatic radical, optionally at least monosubstituted; a C3_8 cycloaliphatic group optionally containing at least one heteroatom as a ring member, saturated or unsaturated, optionally at least monosubstituted, which may be fused with an optionally at least monosubstituted mono or polycyclic ring system; or an optionally at least monosubstituted, 5 or 6 membered aryl or heteroaryl group, which may be fused with a mono- or polycyclic ring system optionally at least monosubstituted and / or linked through a methylene (-CH2-) or ethylene group (-CH2- CH2) -, preferably R7 and R8, identical or different, represent a hydrogen atom or a C6_6 alkyl radical. 18. - Drug according to one or more of claims 11 to 17, characterized in that it comprises at least one compound of general formula I wherein R1 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, R2 represents a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, R3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, in which each of these groups may be substituted with one or more C? alkyl groups? _6, or R represents a residue -NR4R5-, one of the residues R4 and R5 represents a hydrogen atom and the other of these residues R4 and R5 represents an optionally at least monosubstituted pyrrolidinyl group; an optionally at least monosubstituted piperidinyl group; an optionally at least monosubstituted piperazinyl group; an optionally at least monosubstituted triazolyl group; a group -SO2-R6-; or a group -NR7R8 ~, or R4 and R5, identical or different, represent a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group or a tertiary group -butyl, R6 represents a C6_6 alkyl group, a saturated, optionally at least monosubstituted cycloaliphatic group, which may be fused with a monocyclic or polycyclic ring system; or a phenyl group, which is optionally substituted by one or more C? _6 alkyl groups, and R and R8, identical or different, represent a hydrogen atom or a C? _6 alkyl radical. optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding N-oxide of the same, a corresponding salt thereof or a corresponding solvate thereof. 19. - Drug according to one or more of claims 11 to 17, characterized in that it comprises at least one compound of general formula I wherein R1 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of linear or branched C6-6alkyl, linear or branched C6-6alkoxy, F, Cl, Br, I, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R, SH, SRA SOR1, S02R \ NH2,? HR \? R'R1 \ - (C = 0) -NH2, - (C = 0) -? HR? and - (C = 0) -? R'R? , where R 'and R? in each case independently represent an alkyl group of 1 to 6 linear or branched carbon atoms, R 2 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of C? _6 alkyl linear or branched, linear or branched C6-6 alkoxy, F, Cl, Br, I, CH2F, CHF2, CF3, C ?, OH,? 02, - (C = 0) -R ?, SH, SR, SOR1, S02R \? H2,? HR1,? R'R1? , - (C = 0) -NH2, - (C = 0) -? HR? and - (C = 0) -? R'R1? , wherein R1 and R1 in each case independently represent an alkyl group of 1 to 6 straight or branched carbon atoms, R3 represents a saturated or unsaturated C3-8 cycloaliphatic group, said C3_8 cycloaliphatic group being optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of linear or branched C6-6 alkyl, linear or branched C6-6 alkoxy, OH, F, Cl, Br, I, C ?, CH2F, CHF2, CF3 and oxo (= 0) and wherein said C3-8 cycloaliphatic group may contain 1, 2 or 3 heteroatoms independently selected from the group • 3 consisting of N, 0 and S as ring members, or R represents a group -NRR5-, R4 represents a hydrogen atom or a linear or branched C6-6 alkyl group, R5 represents a linear C6-6 alkyl group or branched; a group -S02-R6-; a C3-8 saturated or unsaturated cycloaliphatic group, said cycloaliphatic group being from 3 to 8 carbon atoms optionally substituted with 1, 2, 3 or 4 substituents independently selected from the group consisting of linear or branched C1-6 alkyl group, a linear or branched C6-6 alkoxy group, OH, F, Cl, Br, I, CN, CHF, CHF2, CF and oxo (= 0) and said C3_8 cycloaliphatic group may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of N, O and S as ring members, and R6 represents a phenyl group, which is optionally substituted with 1, 2 , 3, 4 or 5 substituents independently selected from the group consisting of a linear or branched C6-6 alkyl group, a linear or branched C6-6 alkoxy group, F, Cl, Br, I, CH2F, CHF2, CF3, CN, OH, N02, - (C = 0) -R \ SH, SR1, SOR1, SOzR1, NH2, NHR1, NR 'R1 1, - (C = 0) -? H2, - (CA ^ -? HR1 and - (C = 0) -? R'R11, wherein R1 and R11 in each case independently represent a C? _6 alkyl group linear or branched, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or an N - corresponding oxide thereof, a corresponding salt thereof or a corresponding solvate thereof. 20. - Medicament according to one or more of claims 11 to 17 and 19, characterized in that it comprises at least one compound of general formula I wherein R1 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, F, Cl, Br and CF3, R2 represents a phenyl group, which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, F , Cl, Br and CF3, R3 represents a pyrrolidinyl group, a piperidinyl group or a piperazinyl group, in which each of these groups can be substituted with one or more C6-6 alkyl groups, or R3 represents a -NR4R5- moiety , R4 represents a hydrogen atom or a linear or branched C6-6 alkyl group, R5 represents a linear or branched C6-6 alkyl group; a group -S02-R6-; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a homo-piperazinyl group; a morpholinyl group; a triazolyl group; each may be one of the heterocyclic rings substituted with one or more alkyl groups of 1 to 6 identical or different carbon atoms, and R6 represents a phenyl group, which is optionally substituted by one or more C? _6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, at any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof or a corresponding solvate thereof. 21. - Medicament according to one or more of claims 11 to 20, characterized in that it comprises at least one compound of general formula I wherein R1 represents a phenyl ring, which is monosubstituted with a halogen atom, preferably a chlorine atom, in its 4-position, R 2 represents a phenyl ring, which is disubstituted with two halogen atoms, preferably chlorine atoms, in their positions 2 and 4, R 3 represents a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a homo-piperazinyl group, a group morpholinyl or a moiety -NR4R5-, R4 represents a hydrogen atom or a linear or branched C6-6 alkyl group, R5 represents a linear or branched C6-6 alkyl group; a remainder S02-R6; a pyrrolidinyl group; a piperidinyl group; a piperazinyl group; a homo-piperazinyl group; a morpholinyl group; a triazolyl group, each of the heterocyclic rings may be substituted with one or more identical or different C? _6 alkyl groups, and R6 represents a phenyl group which is optionally substituted with one or more C? _6 alkyl groups, which may be identical or different, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or an N- oxide corresponding thereto, a corresponding salt thereof or a corresponding solvate thereof. 22. - Medicament according to one or more of claims 11 to 21, characterized in that it comprises at least one compound selected from the group consisting of: N-piperidinyl-5- (4-chloro-phenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carboxamide, [1,2,4] -triazol-4-yl-amide of 5- (4-chloro-phenyl) -1- (2, 4-) dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid, 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid (4-methyl-piperazin-1-yl) -amide. , 5- (4-Chloro-phenyl) -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazole-3-carboxylic acid diethylamide, [5- (4-chloro-phenyl)] -1- (2,4-dichloro-phenyl) -4,5-dihydro-lH-pyrazol-3-yl] -piperidine-1-yl-methanone, N- [5- (4-chloro-phenyl) -1 - (2,4-dichlorophenyl) -4,5-dihydro-lH-pyrazole-3-carbonyl] -4-methylphenylsufonamide, optionally in the form of a corresponding N-oxide, a corresponding salt or a corresponding solvate. 23. - Drug according to one or more of claims 11-22, for the modulation of cannabinoid receptors, preferably of type 1 cannabinoid receptors (CBi), For the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. 24. - Drug according to one or more of claims 11-22, for the prophylaxis and / or treatment of disorders of food intake, preferably bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin) , more preferably obesity. 25. - Drug according to one or more of claims 11-22, for the prophylaxis and / or treatment of psychosis. 26. - Medication according to one or more of claims 11-22, for the prophylaxis and / or treatment of alcohol abuse and / or addiction, nicotine abuse and / or addiction, abuse and / or drug addiction and / or abuse and / or drug addiction, preferably drug abuse and / or addiction and / or nicotine abuse and / or addiction. 27. - Medicine according to one or more of claims 11-22, for the prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, cancer of colon, bowel cancer and prostate cancer, more preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer. 28. - Medication according to one or more of claims 11-22, for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (for example osteoporosis associated with a genetic predisposition, deficiency of sex hormones , or aging), bone disease associated with cancer or Paget's bone disease; schizophrenia, anxiety, depression, epilepsy, disorders neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, head trauma, brain trauma, stroke, panic attacks, peripheral neuropathy, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremor disorders , compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, drug-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders , itching, pain, or to potentiate the analgesic effect of narcotic and non-narcotic analgesics, or to influence intestinal transit. 29. - Use of at least one substituted pyrazoline compound according to one or more of claims 1-9, including the exempted compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid receptors, preferably of cannabinoid receptors type 1 (CBi), for the prophylaxis and / or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrine system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders. 30. - Use of at least one substituted pyrazoline compound according to one or more of claims 1-9, including the exempted compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of disorders of food intake, preferably bulimia, anorexia, cachexia, obesity, diabetes mellitus type II (diabetes mellitus not dependent on insulin), more preferably obesity. 31. - Use of at least one substituted pyrazoline compound according to one or more of claims 1-9, including the exempted compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of psychoses. 32. - Use of at least one substituted pyrazoline compound according to one or more of claims 1-9, including the excepted compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of abuse and / or alcohol addiction, nicotine abuse and / or addiction, drug abuse and / or addiction and / or drug abuse and / or addiction, preferably drug abuse and / or addiction and / or abuse and / or addiction of nicotine. 33. - Use of at least one substituted pyrazoline compound according to one or more of claims 1-9, including the exempted compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, bladder cancer , pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, bowel cancer and prostate cancer, more preferably for the prophylaxis and / or treatment of one or more types of cancer selected from the group consisting of colon cancer, bowel cancer and prostate cancer. 34. - Use of at least one substituted pyrazoline compound according to one or more of claims 1-9, including the exempted compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and / or treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (e.g. osteoporosis associated with a genetic predisposition, deficiency of sex hormones, or aging), bone disease associated with cancer or Paget's disease of the bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, brain trauma, stroke, panic attacks, peripheral neuropathy, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremor disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, drug-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or to enhance the analgesic effect of analgesics narcotics and non-narcotics, or to influence intestinal transit. 35. - Compound optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.